🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Ben Creelan

Moffitt Cancer Center

ORCID: 0000-0002-2728-8070
MedicineImmunology and Microbiology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile
0Author DataRank

Indexed papers

0in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 7 papers. Top paper: “Phase I Study of Taminadenant (PBF509/NIR178), an Adenosine 2A Receptor Antagonist, with or without Spartalizumab (PDR001), in Patients with Advanced Non–Small Cell Lung Cancer”.

Phase I Study of Taminadenant (PBF509/NIR178), an Adenosine 2A Receptor Antagonist, with or without Spartalizumab (PDR001), in Patients with Advanced Non–Small Cell Lung Cancer

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-21-2742
N/A
1.8DataRank · unranked
70 citations

Ben Creelan, Tawee Tanvetyanon, Jhanelle E. Gray, Eric B. Haura, Ram Thapa +13 more

Neoantigen immunogenicity landscapes and evolution of tumor ecosystems during immunotherapy with nivolumab

Nature Medicine(2024)10.1038/s41591-024-03240-y
N/A
0.546DataRank · unranked
37 citations

Nadeem Riaz, Prerana Bangalore Parthasarathy, Vladimir Makarov, Sviatoslav M. Kendall, Seong‐Keun Yoo +16 more

Sirt2 Inhibition Enhances Metabolic Fitness and Effector Functions of Tumor-Reactive T Cells

Cell Metabolism(2020)10.1016/j.cmet.2020.07.008
N/A
0DataRank · unranked
162 citations

Lin Zhang, Nayoung Kim, Min-Hsuan Wang, Cristina Iclozan, Bin Fang +12 more

Data from Phase I Study of Taminadenant (PBF509/NIR178), an Adenosine 2A Receptor Antagonist, with or without Spartalizumab (PDR001), in Patients with Advanced Non–Small Cell Lung Cancer

(2023)10.1158/1078-0432.c.6531020.v1
N/A
0DataRank · unranked
0 citations

Ben Creelan, Tawee Tanvetyanon, Jhanelle E. Gray, Eric B. Haura, R. K. Thapa +13 more

Developing SEMA4A-directed CAR T cells to overcome low BCMA antigen density in multiple myeloma

Cancer Cell(2025)10.1016/j.ccell.2025.09.007
N/A
0DataRank · unranked
4 citations

Francesca Albano, Annamaria Cesarano, Yunfei Wang, Brandon Kale, Kenneth H. Shain +19 more

Data from Phase I Study of Taminadenant (PBF509/NIR178), an Adenosine 2A Receptor Antagonist, with or without Spartalizumab (PDR001), in Patients with Advanced Non–Small Cell Lung Cancer

(2023)10.1158/1078-0432.c.6531020
N/A
0DataRank · unranked
0 citations

Ben Creelan, Tawee Tanvetyanon, Jhanelle E. Gray, Eric B. Haura, R. K. Thapa +13 more

A gene expression platform to predict benefit from adjuvant external beam radiation in resected non-small cell lung cancer

medRxiv(2021)10.1101/2021.01.31.21250879
N/A
0DataRank · unranked
2 citations

Ben Creelan, Jeffrey Peacock, Eric A. Mellon, Youngchul Kim, G. Daniel Grass +7 more